AKAO - Achaogen, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.9178
-0.5022 (-35.37%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.4200
Open0.8950
Bid0.9280 x 1200
Ask0.9400 x 2900
Day's Range0.8899 - 0.9480
52 Week Range0.8899 - 15.0000
Volume10,176,866
Avg. Volume1,239,040
Market Cap42.329M
Beta (3Y Monthly)0.87
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire3 days ago

    Achaogen Announces Pricing of $15 Million Underwritten Public Offering

    Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock and accompanying short-term warrants to purchase up to 15,000,000 shares of its common stock and long-term warrants to purchase up to 15,000,000 shares of its common stock (collectively, the “warrants”). Each share of common stock is being sold together with one short-term warrant to purchase one share of common stock and one long-term warrant to purchase one share of common stock, at a combined price to the public of $1.00 per share of common stock and accompanying warrants, for gross proceeds of $15 million, before deducting underwriting discounts and commissions and offering expenses payable by Achaogen.

  • GlobeNewswire4 days ago

    Achaogen Announces Proposed Public Offering of Common Stock

    Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Achaogen. In addition, Achaogen expects to grant the underwriter of the offering a 30-day option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions.

  • GlobeNewswire4 days ago

    Achaogen Submits Response to ASPR/BARDA Request for Information (RFI) for Antimicrobial Resistance Project BioShield

    Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that it has responded to a Request for Information (RFI) regarding antibacterial products with the potential to treat resistant biothreat pathogens.  The RFI was solicited by the Assistant Secretary for Preparedness and Response (ASPR) / the Biomedical Advanced Research and Development Authority (BARDA) under Project BioShield. The RFI specifically requested information on availabilities and capabilities for procuring, stockpiling and investing in the ongoing development of antibiotic products for commercial use for treatment of multiple biodefense indications, including pneumonic plague and tularemia, for which plazomicin has demonstrated preclinical efficacy.

  • GlobeNewswire4 days ago

    Achaogen Provides Update on Corporate Progress and Key Preliminary Fourth Quarter 2018 Results

    Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today shared certain key preliminary unaudited results for the fourth quarter ended December 31, 2018, and provided an update on its commercial and corporate activities. “As our previously announced review of strategic alternatives continues, I am pleased with the steady progress of the ZEMDRI commercial launch and especially the commitment of the entire company to bringing this important medicine to the infectious disease community,” said Blake Wise, Achaogen’s Chief Executive Officer.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Achaogen and Arcadia Biosciences

    NEW YORK, NY / ACCESSWIRE / December 11, 2018 / Arcadia Biosciences and Achaogen were two winners in the biotech arena on Monday. Achaogen soared over 20% on positive clearance news for the Thermo Scientific QMS Plazomicin Immunoassay. There was no remarkable news from Arcadia Biosciences to explain the jump.

  • GlobeNewswire2 months ago

    Recent Analysis Shows Best Buy Co., News Corporation, Semtech, Achaogen, Infosys, and Galapagos NV Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Dec. 06, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire3 months ago

    Achaogen Announces Multiple Plazomicin Presentations at the American Society of Health Systems Pharmacists (ASHP) Midyear Clinical Meeting

    SOUTH SAN FRANCISCO, Calif., Nov. 26, 2018 -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial.

  • ACCESSWIRE6 months ago

    Achaogen, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Achaogen, Inc. (NASDAQ: AKAO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern Time. To ...